Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

Yuanyang Zhao,1,* Yuxing Chen,1,* Huaying Huang,1 Xi Li,2 Lin Shao,2 Hao Ding1 1Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of China; 2Department of Medicine, Burning Rock Biotech, Guangzhou, 510300,...

Full description

Bibliographic Details
Main Authors: Zhao Y, Chen Y, Huang H, Li X, Shao L, Ding H
Format: Article
Language:English
Published: Dove Medical Press 2021-05-01
Series:OncoTargets and Therapy
Subjects:
nsclc
egfr-mutant
tki
afatinib
apatinib
Online Access:https://www.dovepress.com/significant-benefits-of-afatinib-and-apatinib-in-a-refractory-advanced-peer-reviewed-fulltext-article-OTT

Internet

https://www.dovepress.com/significant-benefits-of-afatinib-and-apatinib-in-a-refractory-advanced-peer-reviewed-fulltext-article-OTT

Similar Items